This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.01332-06v1 44/12/4384    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Traore, H. Articles by Portaels, F. Search for Related Content PubMed PubMed Citation Articles by Traore, H. Articles by Portaels, F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, December 2006, p. 4384-4388, Vol. 44, No. 12
0095-1137/06/$08.00+0     doi:10.1128/JCM.01332-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Direct Detection of Mycobacterium tuberculosis Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe Assay

Microbiology Department, Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium

Received 28 June 2006/ Returned for modification 18 August 2006/ Accepted 4 October 2006

The INNO-LiPA.Rif TB test (LiPA) has only been applied to a limited number of clinical specimens. To assess the utility of this test for detecting Mycobacterium tuberculosis complex DNA and rifampin (RMP) resistance, 420 sputum samples comprising specimens from untreated (n = 160) and previously treated (n = 260) patients from 11 countries in Asia, Africa, Europe, and Latin America were tested. DNA was extracted from sputum samples by using a modification of the Boom's method, while the rpoB core region was amplified by nested PCR. The results were analyzed in conjunction with those obtained by Ziehl-Neelsen (ZN) microscopy and by culture on solid media. The LiPA test was positive for M. tuberculosis complex DNA in 389 (92.9%) specimens, including 92.0% (286 of 311) ZN-positive and 94.5% (103 of 109) ZN-negative specimens. Of these, 30.6% were RMP resistant. In contrast, 74.3% of the specimens were positive for M. tuberculosis by culture, and 30.8% of them were RMP resistant. LiPA detected M. tuberculosis complex DNA in 92.4% (110 of 119) of the culture-positive and 100.0% (41 of 41) of the culture-negative specimens from untreated patients. There was a 99.6% concordance between the RMP resistance as determined by culture and by the LiPA test. With an optimal DNA extraction method, LiPA allows rapid detection of M. tuberculosis complex DNA and RMP resistance directly from sputum specimens. LiPA can still provide useful information when culture fails for various reasons. The rapid availability of this information is necessary to adjust patient treatment and avoid the risk of amplification of drug resistance.

Published ahead of print on 11 October 2006.

This article has been cited by other articles:

• Quezada, C. M., Kamanzi, E., Mukamutara, J., De Rijk, P., Rigouts, L., Portaels, F., Amor, Y. B. (2007). Implementation Validation Performed in Rwanda To Determine Whether the INNO-LiPA Rif.TB Line Probe Assay Can Be Used for Detection of Multidrug-Resistant Mycobacterium tuberculosis in Low-Resource Countries. J. Clin. Microbiol. 45: 3111-3114 [Abstract] [Full Text]  
• Hillemann, D., Rusch-Gerdes, S., Richter, E. (2007). Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. J. Clin. Microbiol. 45: 2635-2640 [Abstract] [Full Text]